APOC3 and fatty liver disease: This protective effect is consistent with APOC3 inhibition via volanesorsen reducing hepatic steatosis in patients with hypertriglyceridemia [49], and substantial evidence suggests APOC3 deficiency, unlike APOB deficiency, is cardioprotective without causing steatosis [50–52].